SAB Biotherapeutics
SABS | NASDAQ
$3.00
+$0.04 (+1.35%)
At close: Nov 16, 2026, 4:00 PM ET
$3.00
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 4:10 PM ET
SAB Biotherapeutics Company Profile
Company profile explainedCompany Profile
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Key Executives
| Name | Position |
|---|---|
| Samuel J. Reich | CEO & Director |
| Christoph Bausch | Executive Vice President & Chief Operating Officer |
| Lucy To | Executive Vice President & Chief Financial Officer |
| Alexandra Kropotova | Executive Vice President & Chief Medical Officer |
| Angie Parizek | Senior Vice President of Clinical Operations |
| Carlos N. Carillo | Senior Vice President of Regulatory Affairs |
| Catherine DeRose | Vice President of Human Resources |
| Eddie Joe Sullivan | Co-Founder, President & Director |
| Hua Wu | Senior Vice President of Product Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 22, 2026 | 25-NSE | Filing |
| Oct 13, 2026 | 8-K | Current Report |
| Sep 18, 2026 | 4 | Filing |
| Aug 21, 2026 | 424B3 | Filing |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
SAB Biotherapeutics
| Country | United States |
| IPO Date | Feb 9, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 86 |
| CEO | Samuel J. Reich |
Contact Details
777 W 41st St. Miami Beach,
Florida 33140 United States
Stock Details
| Ticker Symbol | SABS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001833214 |
| CUSIP Number | 78397T202 |
| ISIN Number | US78397T2024 |
| SIC Code | 2836 |
Add to Watchlist
Select watchlists to add or remove SABS